Account
Articles
05.06.2017
EMA has published Q&A document

EMA has published Q&A document to prepare manufacturers for the UK's withdrawal from the EU with reg...

Read more
Articles
05.06.2017
New parallel consultation process

A one stop shop for joint advice between EMA, EUnetHTA and health technology assessment bodies - the...

Read more
Articles
05.04.2017
Brexit into the pharmaceutical access unknown

Given that the UK has formally announced its decision to leave the EU, what are the implications for...

Read more
Articles
05.03.2017
Managed entry agreements

MEAs are also known by other names such as risk-sharing agreements, value-added services, and result...

Read more
Articles
05.01.2017
Launch strategy of Inflectra vs Remicade

The lack of a biosimilar market in the US is largely due to the substantial patent litigations which...

Read more
Articles
05.01.2017
How NICE is coping with managing the CDF

This process aims to be completely transparent , to enable faster patient access to oncology treatme...

Read more
Articles
20.12.2016
PCSK9 Inhibitors commercial flop or slow start

Both payers and physicians do not believe that at the current prices Praluent and Repatha offer sign...

Read more
Articles
05.12.2016
Theory of multiple criteria decision analysis

Multi-criteria decision analysis (MCDA) is a potentially useful tool that can be used to support dec...

Read more
Articles
21.11.2016
Potential changes to NICE

NICE has recently published a consultation on changes to its appraisal process to "fast track" some ...

Read more
Articles
14.11.2016
Early scientific advice procedures in the EU

This analysis compares the different methods of seeking payer scientific advice, including EMA joint...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.